Patents Assigned to Charlesson, LLC
  • Curcumin analog compositions and related methods
    Patent number: 8329757
    Abstract: Novel curcumin-analog compounds are disclosed that are antioxidants useful in inhibition of pro-inflammation, angiogenic, and vascular permeability factors and elimination of reactive oxygen species. The curcumin compounds specifically inhibit VEGF and are useful in treating various diseases that are mediated through the oxidative stress pathway, including those that are characterized by inflammation, angiogenesis, or vascular leakage.
    Type: Grant
    Filed: October 14, 2009
    Date of Patent: December 11, 2012
    Assignee: Charlesson, LLC
    Inventor: Danyang Chen
  • 1-ACETYL-5-HYDROXYANTHRACENE-9,10-DIONE FOR TREATMENT OF RETINAL DISEASE
    Publication number: 20120059067
    Abstract: A composition may include a pharmaceutical carrier and an amount, therapeutically effective for the treatment of a retinal disease, of CLT-005 (1-acetyl-5-hydroxyanthracene-9,10-dione), wherein the retinal disease is characterized by at least one of inflammation, angiogenesis, or neovascularization, and wherein the composition is prepared for administration topically. The composition may be administered topically to a subject's eye.
    Type: Application
    Filed: November 11, 2011
    Publication date: March 8, 2012
    Applicant: CHARLESSON, LLC
    Inventor: Rafal A. Farjo
  • STAT3 inhibiting compositions and methods
    Patent number: 8058316
    Abstract: A composition may include a pharmaceutical carrier and an amount, therapeutically effective for the treatment of a retinal disease, of CLT-005 (1-acetyl-5-hydroxyanthracene-9,10 -dione), wherein the retinal disease is characterized by at least one of inflammation, angiogenesis, or neovascularization, and wherein the composition is prepared for administration intravitreally. The composition may be administered intravitreally to a subject's eye.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: November 15, 2011
    Assignee: Charlesson, LLC
    Inventor: Rafal A. Farjo
  • STAT3 INHIBITING COMPOSITIONS AND METHODS
    Publication number: 20110077306
    Abstract: STA-21-related compounds, for example CLT-005, are shown to prevent dimerization of STAT3, thereby inhibiting STAT3 activity. Inhibition of STAT3 activity is shown to reduce intraocular inflammation and neovascularization, symptoms of eye-related diseases such as age-related macular degeneration. Inhibition of STAT3 prevents STAT3 from transcriptionally activating downstream gene targets that are known to be associated with retinal inflammation and neovascularization and such disorders as age-related macular degeneration.
    Type: Application
    Filed: December 10, 2010
    Publication date: March 31, 2011
    Applicant: CHARLESSON, LLC
    Inventor: Rafal A. Farjo
  • PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA
    Publication number: 20100247659
    Abstract: Novel methods are provided to prevent blindness associated with diabetic macular edema by administration of a phenylphthalimide analog. Additionally, sustainability of the effect of administration of the phenylphthalimide analog is improved via encapsulation with poly(lactic-co-glycolic acid) nanoparticles. Finally, a novel method for synthesizing (2,6-diisopropylphenyl)-5-amino-1H-isoindole-1,3-dione is disclosed.
    Type: Application
    Filed: July 24, 2009
    Publication date: September 30, 2010
    Applicant: Charlesson, LLC
    Inventors: Dumitru Ionescu, CherylAnn Love, Danyang Chen, Ronald Andrew Wassel